Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia



Status:Terminated
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/25/2018
Start Date:December 29, 2015
End Date:July 5, 2017

Use our guide to learn which trials are right for you!

A Phase 1b/2 Study of Idelalisib in Combination With BI 836826 in Subjects With Chronic Lymphocytic Leukemia

This study consists of 2 parts: Phase 1b and Phase 2. Phase 1b will evaluate the safety and
tolerability of the combination of idelallisib with the anti-CD37 monoclonal antibody BI
836826 in participants with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and
establish the maximum recommended Phase 2 combination dose (highRP2D) as well as an alternate
lower recommended Phase 2 combination dose (lowRP2D). Phase 2 will determine the rates of
complete response (CR) and of minimal residual disease (MRD) negativity with the combination
at the highRP2D and the lowRP2D in participants with R/R CLL.

The Phase 2 portion of this study will not occur.


Key Inclusion Criteria:

- Diagnosis of B-cell CLL, established according to International Workshop on Chronic
Lymphocytic Leukemia (IWCLL) criteria and having received at least 2 prior treatment
regimens

- CLL that warrants treatment

- Clinically quantifiable disease burden defined as:

- For Phase 1b individuals: absolute lymphocyte count (ALC) > 5000/μL in peripheral
blood.

- For Phase 2 individuals either:

- At least 1 node ≥ 2 cm on computed tomography (CT) or magnetic resonance
imaging (MRI) or

- bone marrow exam is performed at screening and demonstrates quantifiable
CLL.

- Discontinuation of all cytotoxic chemotherapy and anti-CD20 antibody therapy for ≥ 4
weeks, alemtuzumab for ≥ 8 weeks, targeted therapy for ≥ 2 weeks, and investigational
therapy for ≥ 3 weeks before enrollment (Phase 1b) or randomization (Phase 2). For
individuals with relapsed CLL most recently treated with B-cell receptor (BCR) pathway
inhibitors who, in the opinion of the investigator, will not tolerate waiting 3 weeks,
a washout period of > 5 half-lives is allowed. If on a systemic corticosteroid, the
dose must be stable for the previous 4 weeks.

- Eastern Cooperative Oncology Group (ECOG) score of ≤ 2

Key Exclusion Criteria:

- Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
transformation)

- Known presence of myelodysplastic syndrome

- History of a non-CLL malignancy except for the following: adequately treated local
basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ,
superficial bladder cancer, asymptomatic prostate cancer without known metastatic
disease and with no requirement for therapy or requiring only hormonal therapy and
with normal prostate-specific antigen for ≥ 1 year prior to enrollment, other
adequately treated Stage 1 or 2 cancer currently in complete remission, or any other
cancer that has been in complete remission for ≥ 2 years.

- Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
enrollment

- Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active
hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary
biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the
liver, or portal hypertension.

- History of drug-induced pneumonitis

- Ongoing inflammatory bowel disease

- Ongoing alcohol or drug addiction

- History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

- Ongoing systemic immunosuppressive therapy other than corticosteroids

- History of prior therapy with any phosphatidylinositol 3-kinase (PI3K) inhibitor
(including idelalisib), or any anti-CD37 agent

- Ongoing infection with, or treatment or prophylaxis for, CMV within the past 28 days.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
We found this trial at
2
sites
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials